Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 367

Results For "IMI"

3748 News Found

SPARC announces positive results from Phase 3 trial of PDP-716
News | May 15, 2021

SPARC announces positive results from Phase 3 trial of PDP-716

The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day


Alembic gets USFDA approval for Lurasidone Hydrochloride tablets
News | May 15, 2021

Alembic gets USFDA approval for Lurasidone Hydrochloride tablets

Lurasidone Hydrochloride tablets are also indicated for adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder


Dr. Reddy's Sputnik V India price is Rs. 995.40
News | May 15, 2021

Dr. Reddy's Sputnik V India price is Rs. 995.40

The company is working closely with its six manufacturing partners in India


Granules to donate 16 crores Paracetamol tablets to Telangana
News | May 15, 2021

Granules to donate 16 crores Paracetamol tablets to Telangana

The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months


Zydus Cadila entity to sell its India focused animal health business to a consortium
News | May 13, 2021

Zydus Cadila entity to sell its India focused animal health business to a consortium

The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,


Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India
News | May 13, 2021

Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India

The agreement will help ensure wider reach and access to patients in India


Lupin reports Q4FY21 consolidated PAT of Rs. 460.36 Cr
News | May 13, 2021

Lupin reports Q4FY21 consolidated PAT of Rs. 460.36 Cr

It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021


Vivimed Labs to manufacture, market Favipiravir tablets
News | May 11, 2021

Vivimed Labs to manufacture, market Favipiravir tablets

The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India


CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating
News | May 11, 2021

CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating

The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.


Jubilant Pharma wins over Bracco's legal appeals in the US Court of Appeals
News | May 10, 2021

Jubilant Pharma wins over Bracco's legal appeals in the US Court of Appeals

Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office